Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by thasison Jun 26, 2013 2:04am
1044 Views
Post# 21572822

Stockwatch summary on MF and AMB dispute

Stockwatch summary on MF and AMB dispute

Bill Sheriff's Americas Bullion Royalty Corp. (AMB) slipped 1.5 cents to 11 cents, an all-time low, on 959,000 shares. This week the company is having some trouble with one of its creditors, MF Investment Holdings, which has accused the company of defaulting on a $35-million loan. So far, Americas has drawn down only $10-million of the loan, an amount which is not due until 2015, under the September, 2012, loan agreement. The company borrowed the money to bring its Brewery Creek gold project in the Yukon closer to production. Before it can draw down the second $10-million tranche it must complete a prefeasibility study and agree to sell Brewery's first 500,000 ounces of gold to MF at a 1.5-per-cent discount to spot price. Americas says it has not defaulted and has hired a lawyer to defend itself.

Brewery Creek is the company's only remaining exploration property. It became a royalty company earlier this year, changing its name to Americas Bullion from Golden Predator in February. Before the change, Golden Predator passed along its group of Nevada gold properties to Mr. Sheriff's other company.

Bullboard Posts